
Glenmark inks pact with SaNOtize to produce, market anti-COVID nasal spray in India, other countries
The Hindu
Canadian biotech firm SaNOtize Research & Development Corp. has entered into an exclusive long-term agreement with Glenmark Pharmaceuticals Ltd. for manufacturing, marketing and distribution o
Canadian biotech firm SaNOtize Research & Development Corp. has entered into an exclusive long-term agreement with Glenmark Pharmaceuticals Ltd. for manufacturing, marketing and distribution of its nitric oxide nasal spray (NONS) used to treat COVID-19 in India. Glenmark would also be handling other Asian markets, including Singapore, Malaysia, Hong Kong, Taiwan, Nepal, Brunei, Cambodia, Laos, Myanmar, Sri Lanka, Timor-Leste and Vietnam. “In March, SaNOtize’s clinical trials showed NONS was a safe and effective antiviral treatment to prevent the transmission of COVID-19, shorten its course, and reduce the severity of symptoms,” Glenmark said in a statement.More Related News